BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 9469355)

  • 1. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.
    Bacci G; Ferrari S; Delepine N; Bertoni F; Picci P; Mercuri M; Bacchini P; Brach del Prever A; Tienghi A; Comandone A; Campanacci M
    J Clin Oncol; 1998 Feb; 16(2):658-63. PubMed ID: 9469355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs.
    Bacci G; Ferrari S; Picci P; Zolezzi C; Gherlinzoni F; Iantorno D; Cazzola A
    J Chemother; 1996 Dec; 8(6):472-8. PubMed ID: 8981189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
    Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
    Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Ferrari S; Ruggieri P; Cefalo G; Tamburini A; Capanna R; Fagioli F; Comandone A; Bertulli R; Bisogno G; Palmerini E; Alberghini M; Parafioriti A; Linari A; Picci P; Bacci G
    J Clin Oncol; 2012 Jun; 30(17):2112-8. PubMed ID: 22564997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy.
    Ferrari S; Bacci G; Picci P; Mercuri M; Briccoli A; Pinto D; Gasbarrini A; Tienghi A; Brach del Prever A
    Ann Oncol; 1997 Aug; 8(8):765-71. PubMed ID: 9332684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
    Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
    Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
    Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
    J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group.
    Provisor AJ; Ettinger LJ; Nachman JB; Krailo MD; Makley JT; Yunis EJ; Huvos AG; Betcher DL; Baum ES; Kisker CT; Miser JS
    J Clin Oncol; 1997 Jan; 15(1):76-84. PubMed ID: 8996127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.
    Saeter G; AlvegÄrd TA; Elomaa I; Stenwig AE; Holmström T; Solheim OP
    J Clin Oncol; 1991 Oct; 9(10):1766-75. PubMed ID: 1717666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,
    Bacci G; Ferrari S; Bertoni F; Picci P; Bacchini P; Longhi A; Donati D; Forni C; Campanacci L; Campanacci M
    Clin Orthop Relat Res; 2001 May; (386):186-96. PubMed ID: 11347833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin.
    Bacci G; Picci P; Ruggieri P; Mercuri M; Avella M; Capanna R; Brach Del Prever A; Mancini A; Gherlinzoni F; Padovani G
    Cancer; 1990 Jun; 65(11):2539-53. PubMed ID: 2337871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate levels and outcome in osteosarcoma.
    Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
    Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies.
    Bacci G; Picci P; Ferrari S; Casadei R; Brach Del Prever A; Tienghi A; Mancini A
    J Chemother; 1993 Aug; 5(4):237-46. PubMed ID: 8229152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute.
    Bacci G; Ferrari S; Forni C; Mercuri M; Picci P; Bertoni F; Capanna R; Manfrini M; Donati D; Brach Del Prever A; Baldini N
    Chir Organi Mov; 1996; 81(4):369-82. PubMed ID: 9147928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results.
    Bacci G; Avella M; Brach Del Prevert A; Capanna R; Fiorentini G; Malaguti C; Picci P; Rosito P; Campanacci M
    Chemioterapia; 1988 Apr; 7(2):138-42. PubMed ID: 3165058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
    Bacci G; Mercuri M; Briccoli A; Ferrari S; Bertoni F; Donati D; Monti C; Zanoni A; Forni C; Manfrini M
    Cancer; 1997 Jan; 79(2):245-54. PubMed ID: 9010097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.